Interest of Relaxation From Patients With Pain Due to Migraine

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00904527

Acronym

MIGREL

Enrollment

Registered

2009-05-19

Start date

2006-06-30

Completion date

2009-04-30

Last updated

2015-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Keywords

Relaxation (Schultz), Migraine, antipain center

Brief summary

The purpose of this study is to determine whether relaxation (autogenic training of Schultz) is effective in treatment for migraine.

Detailed description

This randomized, multicenter study compares 2 parallel groups of patients with migraine : * I: patients are treated with relaxation + medical treatment (beta-bloquant or Oxetorone)+ patients' education * II: patients are treated only with medical treatment + patients' education. Visit 1 : 1 month before randomization for patient's selection and baseline data Visit 2 (J0): inclusion (randomization) During the first 2 months patients from group I benefit from relaxation consultations. Visit 3 (2 months after randomization)and visit 4 (4 months after randomization) : evaluation of the efficacy of the two treatment strategies. Primary endpoint : \- number of days with migraine per month from J0 to visit 4. Secondary endpoints : * monthly drug consumption * percentage of patients who respond (50 % frequency reduction) * quality of life (SF 36) Each day, patients note in a notebook if a migraine appears and its intensity.

Interventions

BEHAVIORALrelaxation (Schultz)

Patients have relaxation consultations during 2 months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* age \> 18 years * 5 to 14 days of migraines per month

Exclusion criteria

* Headache by medication abuse * Patients who already know relaxation technics * Depression * Contra indication of using beta-bloquant or Oxetorone

Design outcomes

Primary

Measure	Time frame
Comparison of reduction of migraine frequency between the 2 groups (with or without relaxation)	4 months

Secondary

Measure	Time frame
Comparison between the 2 groups of intensity of migraine, medication use and quality of life	4 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026